Cargando…

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction

Patients receiving therapy for the secondary prevention of myocardial infarction (MI) are still at high risk of a major cardiovascular event or death despite the use of currently available treatment strategy. Vorapaxar, an oral protease-activated receptor antagonist, is a novel antiplatelet drug tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kehinde, Obamiro, Kunle, Rotimi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832913/ https://www.ncbi.nlm.nih.gov/pubmed/27134460 http://dx.doi.org/10.4103/0975-7406.171690

Ejemplares similares

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Factors that influence pharmacists' efforts in addressing substance use in Nigeria: An exploratory study
por: Rotimi, Kunle, et al.
Publicado: (2022)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade
por: Atar, Dan, et al.
Publicado: (2014)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Considering Cause and Effect of Immune Cell Aging on Cardiac Repair after Myocardial Infarction
por: Tobin, Stephanie W., et al.
Publicado: (2020)

Secondary Prevention of Myocardial Infarction in People Living With HIV Infection
por: Erqou, Sebhat, et al.
Publicado: (2020)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Randomised controlled trial of a secondary prevention program for myocardial infarction patients ('ProActive Heart'): study protocol. Secondary prevention program for myocardial infarction patients
por: Hawkes, Anna L, et al.
Publicado: (2009)

Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction
por: Weiss, Thomas W., et al.
Publicado: (2016)

Secondary Prevention of Myocardial Infarction With Nonpharmacologic Strategies in a Medicaid Cohort
por: Oberg, Erica B., et al.
Publicado: (2009)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Going beyond the mean: economic benefits of myocardial infarction secondary prevention
por: von Wyl, Viktor, et al.
Publicado: (2020)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Public Awareness of Bowel Cancer Risk Factors, Symptoms and Screening in Tasmania, Australia: A Cross-Sectional Study
por: Lee, Simone M., et al.
Publicado: (2022)

Considerations for Training and Workforce Development to Enhance Rural and Remote Ophthalmology Practise in Australia: A Scoping Review
por: Obamiro, Kehinde, et al.
Publicado: (2022)

Assessment of quality and readability of internet-based health information related to commonly prescribed angiotensin receptor blockers
por: Oloidi, Anuoluwapo, et al.
Publicado: (2020)

Beta-Blockers for the Secondary Prevention of Myocardial Infarction in People with Dementia: A Systematic Review
por: Lanham, David, et al.
Publicado: (2019)

Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction
por: Solomon, Matthew D., et al.
Publicado: (2020)

Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction
por: Pan, Qi, et al.
Publicado: (2021)

Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways
por: Pang, Jianliang, et al.
Publicado: (2019)

Long-term secondary prevention of acute myocardial infarction (SEPAT) – guidelines adherence and outcome
por: Ergatoudes, Constantinos, et al.
Publicado: (2016)

Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction
por: Halvorsen, Sigrun, et al.
Publicado: (2016)

Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus
por: Jørgensen, Casper H, et al.
Publicado: (2014)

Association of secondary prevention medication use after myocardial infarction with mortality in hemodialysis patients
por: Lin, Ting-Yun, et al.
Publicado: (2022)

Acute Myocardial Infarction Secondary to Paradoxical Embolism
por: Alenezi, Abdullah R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jbo5k138889uajopn266vh2ofv